Eli Lilly (LLY) has agreed to acquire three vaccine developers in transactions valued at up to nearly $4 billion combined, marking a significant push by the weight-loss drug market leader into infectious-disease prevention.

Global health authorities and a clutch of drugmakers are racing to assemble medical defences against an Ebola outbreak in eastern Democratic Republic of Congo, where a rarer strain of the virus has left the world without a single approved vaccine or therapy to deploy.

UCB has reported data it says marks a milestone in the crowded market for psoriatic arthritis treatments, with its drug bimekizumab beating AbbVie's risankizumab in a direct comparison of joint outcomes.

South Korean biotechnology company AriBio said it has received an initial $10mn payment from China's Fosun Pharma (02196.HK) under a global exclusive licensing agreement for its Alzheimer's drug candidate AR1001, with the funds transferred just ten days after the deal was announced.

Drugmakers have wagered billions of dollars on a new class of cancer drugs targeting two well-known biological pathways — PD-1 and VEGF — but analysts say the industry's fixation on lung cancer may be obscuring a more compelling opportunity elsewhere.

Global biopharma dealmaking is surging toward its strongest year since 2019, with $106 billion in transactions across 201 deals recorded so far in 2026, according to PitchBook data. If the current pace holds, total deal value could exceed $250 billion by year-end.

AbbVie (ABBV) is eliminating 85 positions at its Irvine, California campus, with the cuts set to take effect July 20, according to a filing under the state's Worker Adjustment and Retraining Notification Act. The layoffs affect the company's eye care business, which operates alongside aesthetics, neurotoxin and neuro-psychiatry functions at the 54-acre, one million square foot site.

AstraZeneca remained in focus among investors as analysts continued assessing whether the pharma giant’s recent share performance fully reflected its long-term growth outlook.

Astellas Pharma (ALPMY) is counting on high-margin treatments including cancer therapy Padcev and eye drug Izervay to hit a five-year target of at least ¥4.3 trillion ($27 billion) in cumulative core operating profit before research and development costs.

Europe's medicines regulator has recommended approval of Novo Nordisk's (NVO) oral Wegovy, paving the way for the first weight-loss pill to reach the European market and handing the Danish drugmaker a lead over US rival Eli Lilly (LLY).

Europe's medicines regulator has recommended approval of AstraZeneca's (AZN) experimental breast cancer treatment camizestrant, putting it at odds with an American advisory panel that raised concerns about the drug last month.

The blockbuster class of weight-loss and diabetes medicines known as GLP-1 drugs may carry an unexpected benefit for cancer patients, according to four new studies suggesting the treatments are associated with slower tumor progression and improved survival rates.

Eli Lilly reported new data showing its GLP-1 therapy Mounjaro delivered stronger outcomes than other commonly used treatments in patients with recently diagnosed type 2 diabetes.

Bristol Myers Squibb reported positive Phase 3 results for experimental multiple myeloma therapy mezigdomide, strengthening its next-generation oncology pipeline as the company prepares for increased generic competition to key legacy products.

Shares in BridgeBio Pharma (BBIO) rose 5.8 per cent on Monday after the rare-disease specialist submitted a New Drug Application to the FDA for encaleret and reported strong late-stage clinical data across two programmes, raising hopes that the company is evolving beyond its dependence on a single product.

Sun Pharmaceutical Industries (SUNPHARMA) reported quarterly profit ahead of analyst expectations on Friday, driven by strong demand for its higher-margin specialty medicines, but rising costs eroded profitability and pushed shares lower.

AstraZeneca (AZN) and its Japanese partner Daiichi Sankyo (DSNKY) have secured US regulatory approval for Datroway in triple-negative breast cancer, marking a significant milestone in an intensifying battle with Gilead Sciences (GILD) for dominance in one of oncology's most contested markets.

Guggenheim has initiated coverage of Avalyn Pharma (AVLN) with a buy rating and a price target of $80, implying roughly 177 per cent upside from its current level of $28.84 and valuing the company at $1.21bn on a market capitalisation basis.

Nestlé (NSRGY) and Danone (DANOY) are facing renewed regulatory and reputational pressure after a joint investigation by French, Belgian and Swiss public broadcasters alleged that both companies were slow to alert European authorities to the presence of a harmful toxin in infant formula products.

Takeda Pharmaceutical (TAK) faces a damages bill that could reach $2.5bn after a federal jury in Boston found the Japanese drugmaker liable in what legal experts are calling a landmark antitrust case, the first time a pharmaceutical company has been found liable by a federal jury in a so-called pay-for-delay suit.